Immunotherapy

Global Cancer Immunotherapy Market is Forecast to Hit $100 Billion by 2022

Monday, October 14, 2019 - 1:00pm

Today, cancer immunotherapy drugs have captured nearly 50% of the overall oncology drugs market, generating about $54 billion in 2016 alone and are forecast to surpass $100 billion in 2022.

Key Points: 
  • Today, cancer immunotherapy drugs have captured nearly 50% of the overall oncology drugs market, generating about $54 billion in 2016 alone and are forecast to surpass $100 billion in 2022.
  • An overview of cancer immunotherapy that includes monoclonal antibodies, ADC's, cancer vaccines and non-specific cancer immunotherapies and CAR T therapies.
  • Overall global cancer therapeutics market, leading market players and the bestselling cancer drugs.
  • To that end, the Cancer Immunotherapy Market is forecast to hit $100 billion by 2022.

Global Cancer Immunotherapy Market is Forecast to Hit $100 Billion by 2022

Monday, October 14, 2019 - 1:00pm

Today, cancer immunotherapy drugs have captured nearly 50% of the overall oncology drugs market, generating about $54 billion in 2016 alone and are forecast to surpass $100 billion in 2022.

Key Points: 
  • Today, cancer immunotherapy drugs have captured nearly 50% of the overall oncology drugs market, generating about $54 billion in 2016 alone and are forecast to surpass $100 billion in 2022.
  • An overview of cancer immunotherapy that includes monoclonal antibodies, ADC's, cancer vaccines and non-specific cancer immunotherapies and CAR T therapies.
  • Overall global cancer therapeutics market, leading market players and the bestselling cancer drugs.
  • To that end, the Cancer Immunotherapy Market is forecast to hit $100 billion by 2022.

ISA Pharmaceuticals B.V. Receives EUR 20m Loan From European Investment Bank

Monday, October 14, 2019 - 9:00am

LEIDEN, Netherlands, Oct. 14, 2019 /PRNewswire/ -- The European Investment Bank and ISA Pharmaceuticals have signed a EUR 20 million loan agreement to support the development of ISA's therapy for cancers caused by the Human Papillomavirus type 16 (HPV16).

Key Points: 
  • LEIDEN, Netherlands, Oct. 14, 2019 /PRNewswire/ -- The European Investment Bank and ISA Pharmaceuticals have signed a EUR 20 million loan agreement to support the development of ISA's therapy for cancers caused by the Human Papillomavirus type 16 (HPV16).
  • ISA Pharmaceuticals has developed a novel therapy, ISA101b, which targets HPV16-positive cancers through the specific activation of the patient's own immune system.
  • The European Investment Bank (EIB) is the long-term lending institution of the European Union, owned by its Member States.
  • ISA Pharmaceuticals B.V. is an immunotherapy company developing rationally designed, fully synthetic immunotherapeutics against cancer and persistent viral infections.

ISA Pharmaceuticals B.V. Receives EUR 20m Loan From European Investment Bank

Monday, October 14, 2019 - 9:00am

LEIDEN, Netherlands, Oct. 14, 2019 /PRNewswire/ -- The European Investment Bank and ISA Pharmaceuticals have signed a EUR 20 million loan agreement to support the development of ISA's therapy for cancers caused by the Human Papillomavirus type 16 (HPV16).

Key Points: 
  • LEIDEN, Netherlands, Oct. 14, 2019 /PRNewswire/ -- The European Investment Bank and ISA Pharmaceuticals have signed a EUR 20 million loan agreement to support the development of ISA's therapy for cancers caused by the Human Papillomavirus type 16 (HPV16).
  • ISA Pharmaceuticals has developed a novel therapy, ISA101b, which targets HPV16-positive cancers through the specific activation of the patient's own immune system.
  • The European Investment Bank (EIB) is the long-term lending institution of the European Union, owned by its Member States.
  • ISA Pharmaceuticals B.V. is an immunotherapy company developing rationally designed, fully synthetic immunotherapeutics against cancer and persistent viral infections.

Advaxis and UCLA Enter Collaboration for Glioblastoma Immunotherapy Discovery Research

Thursday, October 10, 2019 - 1:00pm

Advaxis, Inc. (Nasdaq: ADXS), a clinical-stage biotechnology company focused on the discovery, development and commercialization of immunotherapy products, today announced a research collaboration agreement with the University of California Los Angeles (UCLA) to conduct preclinical studies evaluating the Companys Lm technology in mouse tumor models of glioblastoma multiforme (GBM).

Key Points: 
  • Advaxis, Inc. (Nasdaq: ADXS), a clinical-stage biotechnology company focused on the discovery, development and commercialization of immunotherapy products, today announced a research collaboration agreement with the University of California Los Angeles (UCLA) to conduct preclinical studies evaluating the Companys Lm technology in mouse tumor models of glioblastoma multiforme (GBM).
  • Specifically, the collaboration with Dr. Vaithi Arumugaswamis group at UCLAs Department of Molecular and Medical Pharmacology will investigate anti-tumor immunity and anti-tumor responses generated by Lm vaccines that express diverse glioblastoma neoantigens.
  • Advaxis, Inc. is a clinical-stage biotechnology company focused on the discovery, development and commercialization of proprietary Lm-based antigen delivery products.
  • To learn more about Advaxis, visit www.advaxis.com and connect on Twitter, LinkedIn, Facebook and YouTube.

CytoSorbents to Present at The MicroCap Rodeo Investor Conference

Thursday, October 10, 2019 - 12:00pm

An archived replay of the webcast will be available for one year following the event.

Key Points: 
  • An archived replay of the webcast will be available for one year following the event.
  • CytoSorbents Corporation is a leader in critical care immunotherapy, specializing in blood purification.
  • These are conditions where the risk of death is extremely high, yet no effective treatments exist.
  • For more information, please visit the Company's websites at www.cytosorbents.com and www.cytosorb.com or follow us on Facebook and Twitter .

City of Hope Is Enrolling Patients in First of Its Kind Clinical Trial for Brain Tumor Patients

Wednesday, October 9, 2019 - 5:00pm

The trial will deliver CAR T cells that target IL13R2 locally to the brain, by direct injection to the tumor site and through infusion into the ventricular system.

Key Points: 
  • The trial will deliver CAR T cells that target IL13R2 locally to the brain, by direct injection to the tumor site and through infusion into the ventricular system.
  • City of Hope was the first to use this type of delivery for glioblastoma patients receiving CAR T treatment, as well as the first to investigate CAR T cells targeting IL13R2.
  • Mustang Bio Inc. (NASDAQ: MBIO) is the exclusive licensee of City of Hope patents covering its IL13R2-specific CAR T cell therapy.
  • Founded in 1913, City of Hope is a leader in bone marrow transplantation and immunotherapy such as CAR T cell therapy .

European Patent Office Grants New Patent Covering Enlivex’s Allocetra™ Immunotherapy Treatment

Tuesday, October 8, 2019 - 12:30pm

Nes-Ziona, Israel, Oct. 08, 2019 (GLOBE NEWSWIRE) -- Enlivex Therapeutics, Ltd., a clinical-stage immunotherapy company, today announced that the European Patent Office granted a new patent (#EP 2 929 015 B1) covering ALLOCETRATM, the companys immunotherapy product.

Key Points: 
  • Nes-Ziona, Israel, Oct. 08, 2019 (GLOBE NEWSWIRE) -- Enlivex Therapeutics, Ltd., a clinical-stage immunotherapy company, today announced that the European Patent Office granted a new patent (#EP 2 929 015 B1) covering ALLOCETRATM, the companys immunotherapy product.
  • This new patent adds intellectual property protection, including methods, uses and pharmaceutical compositions in the EU.
  • Enlivex is a clinical stage immunotherapy company, developing an allogeneic drug pipeline for immune system rebalancing.
  • Immune system rebalancing is critical for the treatment of life-threatening immune and inflammatory conditions which involve an out of control immune system (e.g.

Novel approach based on InVision® liquid biopsy platform predicts response to immune checkpoint inhibitors

Tuesday, October 8, 2019 - 12:00pm

Clive Morris, Chief Executive Officer at Inivata, said: This latest study provides exciting clinical evidence that the InVision ctDNA liquid biopsy platform could potentially be used to predict response to PD-1 inhibitors as well as actionable genomic alterations associated with targeted therapies.

Key Points: 
  • Clive Morris, Chief Executive Officer at Inivata, said: This latest study provides exciting clinical evidence that the InVision ctDNA liquid biopsy platform could potentially be used to predict response to PD-1 inhibitors as well as actionable genomic alterations associated with targeted therapies.
  • Many patients with advanced NSCLC are candidates for immunotherapy, and we hope our novel response prediction approach will help to guide the most appropriate use of such therapies in the future.
  • Dr Nicolas Guibert MD, PhD, Toulouse University Hospital said: Immune checkpoint inhibitors are rapidly changing the treatment landscape for NSCLC but durable clinical benefit is limited to certain subsets of patients.
  • Its InVision platform unlocks essential genomic information from a simple blood draw to transform the care of cancer patients.

Precision Immunotherapy Innovations Transforming Human Health and Wellness, 2019 Report - ResearchAndMarkets.com

Monday, October 7, 2019 - 5:32pm

The "Precision Immunotherapy Innovations Transforming Human Health and Wellness" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Precision Immunotherapy Innovations Transforming Human Health and Wellness" report has been added to ResearchAndMarkets.com's offering.
  • There are numerous companies developing immunotherapy approaches to treat cancer, autoimmune and several other diseases.
  • The current study describes some of the recent advances in immunotherapy, mostly cancer.
  • These include refined cell therapies, stem cell applications in cancer treatment, monoclonal, polyclonal and bispecific antibodies.